Camurus: License Agreement with Lilly - Redeye
Bildkälla: Stockfoto

Camurus: License Agreement with Lilly - Redeye

Redeye views the agreement with Eli Lilly, close second in the obesity space after Novo Nordisk, as strong validation of its FluidCrystal platform.

Redeye views the agreement with Eli Lilly, close second in the obesity space after Novo Nordisk, as strong validation of its FluidCrystal platform.
Börsvärldens nyhetsbrev